NASDAQ:TRDA Entrada Therapeutics Q2 2026 Earnings Results & Report $5.67 +0.14 (+2.53%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$5.66 0.00 (-0.09%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Entrada Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 5, 2026. The company reported EPS of -$1.01 versus the -$0.9738 consensus estimate, while revenue of $0.90 million fell short of the $2.32 million estimate by $1.43 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Entrada Therapeutics EPS ResultsActual EPS-$1.01Consensus EPS -$0.9738Beat/MissMissed by -$0.0363One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEntrada Therapeutics Revenue ResultsActual Revenue$0.90 millionExpected Revenue$2.32 millionBeat/MissMissed by -$1.43 millionYoY Revenue GrowthN/AUpcoming EarningsEntrada Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Entrada Therapeutics Q2 2026 Earnings FAQ Did Entrada Therapeutics beat earnings estimates for Q2 2026? Entrada Therapeutics (NASDAQ:TRDA) reported earnings of -$1.01 per share for Q2 2026, missing the consensus estimate of -$0.9738. The report was announced on Wednesday, August 5, 2026. What was Entrada Therapeutics' revenue for Q2 2026? Entrada Therapeutics reported revenue of $0.90 million for Q2 2026, against a consensus estimate of $2.32 million. When is Entrada Therapeutics' next earnings date? Entrada Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Entrada Therapeutics on the company's earnings history page. Entrada Therapeutics Earnings HeadlinesEntrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying OpportunityOctober 10 at 3:00 AM | seekingalpha.comEntrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | finanznachrichten.deThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields up 1,298%, Reunion Gold up 716%, and Highlander Silver up 741%. Now he has released a new research report on a unique high yielding gold security backed by what he calls the world's best gold mine today, offering a yield now plus long term upside.October 10 at 1:00 AM | Golden Portfolio (Ad)Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)September 5, 2026 | theglobeandmail.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2026 | globenewswire.comSee More Entrada Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email. Email Address About Entrada TherapeuticsEntrada Therapeutics (NASDAQ:TRDA) is a biotechnology company focused on developing medicines that address diseases caused by genetic abnormalities. The company’s research centers on its proprietary Endosomal Escape Vehicle (EEV) platform, which is designed to transport therapeutic cargo into cells and release it from endosomes, potentially enabling treatment of targets that have been difficult to reach with conventional drug-delivery approaches. Entrada is developing EEV-based therapeutics using modalities such as oligonucleotides, including compounds intended to modify RNA or influence gene expression. Its pipeline has included programs for rare genetic and neuromuscular disorders, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The company’s Duchenne programs are designed to promote exon skipping for specific genetic mutations, with the goal of helping cells produce a functional form of dystrophin. Founded in 2016 and headquartered in Boston, Massachusetts, Entrada conducts research and clinical development aimed at serving patients with serious diseases in the United States and other global markets. As a clinical-stage biotechnology company, its products remain in development and are subject to the outcomes of clinical trials, regulatory review and other development requirements.View Entrada Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
